Clinical Trials Browser

Has results × cabozantinib × Dermatologic × Clear all

Melanoma

NCT05200143 2024-09-19

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Phase 2 Terminated

4 enrolled 11 charts

Dermatologic

Melanoma

NCT00940225 2024-04-25

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Phase 2 Completed

730 enrolled 25 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT01709435 2023-12-22

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Phase 1 Completed

41 enrolled 20 charts

CNSDermatologicHead & Neck

Melanoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT02036476 2023-05-09

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Phase 2 Terminated

8 enrolled 7 charts

Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT01835145 2022-08-04

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Phase 2 Completed

47 enrolled 12 charts

Dermatologic

Uveal Melanoma

Clinical Trials

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery